Equities analysts expect Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) to announce earnings of ($0.83) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Eiger Biopharmaceuticals’ earnings. The highest EPS estimate is ($0.76) and the lowest is ($0.90). Eiger Biopharmaceuticals posted earnings of ($1.11) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 25.2%. The business is scheduled to announce its next quarterly earnings report on Monday, March 18th.

On average, analysts expect that Eiger Biopharmaceuticals will report full-year earnings of ($3.44) per share for the current fiscal year, with EPS estimates ranging from ($3.75) to ($2.78). For the next fiscal year, analysts forecast that the business will report earnings of ($2.55) per share, with EPS estimates ranging from ($3.66) to ($0.79). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that cover Eiger Biopharmaceuticals.

A number of brokerages recently weighed in on EIGR. ValuEngine lowered shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. BidaskClub downgraded shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, February 25th. Zacks Investment Research downgraded shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 20th. Wedbush reaffirmed a “buy” rating and set a $43.00 price target on shares of Eiger Biopharmaceuticals in a research note on Tuesday, February 19th. Finally, Robert W. Baird began coverage on shares of Eiger Biopharmaceuticals in a research note on Monday, January 28th. They set an “outperform” rating and a $47.00 price target on the stock. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $31.88.

EIGR opened at $13.31 on Tuesday. The company has a market capitalization of $257.52 million, a price-to-earnings ratio of -2.74 and a beta of 1.48. Eiger Biopharmaceuticals has a 1-year low of $8.20 and a 1-year high of $18.00. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.59 and a quick ratio of 4.59.

In other news, Director Thomas John Dietz bought 5,000 shares of Eiger Biopharmaceuticals stock in a transaction dated Thursday, December 20th. The shares were acquired at an average price of $9.98 per share, with a total value of $49,900.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $99,800. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 7.90% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in EIGR. Jane Street Group LLC purchased a new stake in shares of Eiger Biopharmaceuticals in the fourth quarter valued at $114,000. Dimensional Fund Advisors LP purchased a new position in Eiger Biopharmaceuticals in the 3rd quarter worth about $194,000. Tocqueville Asset Management L.P. purchased a new position in Eiger Biopharmaceuticals in the 3rd quarter worth about $203,000. Millennium Management LLC purchased a new position in Eiger Biopharmaceuticals in the 4th quarter worth about $255,000. Finally, Bank of America Corp DE increased its stake in Eiger Biopharmaceuticals by 49.6% in the 4th quarter. Bank of America Corp DE now owns 25,884 shares of the biotechnology company’s stock worth $263,000 after buying an additional 8,581 shares during the period. 81.76% of the stock is currently owned by institutional investors and hedge funds.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

See Also: What is a Derivative?

Get a free copy of the Zacks research report on Eiger Biopharmaceuticals (EIGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.